Peer-reviewed research examines the relationship between carbon monoxide exposure, oxygen metabolism, and mitochondrial activity in the brain
BOSTON, MASSACHUSETTS — August 21, 2024 — Bioxytran, Inc. (OTCQB: BIXT), a clinical-stage biotechnology company developing carbohydrate-based therapeutics and oxygen transport technologies, today highlighted research published in the British Journal of Healthcare and Medical Research examining the effects of carbon monoxide on mitochondrial activity and brain function.
The peer-reviewed article, titled “The Involvement of Carbon Monoxide in Mitochondrial Activity and Brain Functions,” was authored by Professor Avraham Mayevsky, Chief Technology Officer of MDX Life Sciences, an affiliate of Bioxytran.
The research used the MDX Viewer, a technology developed by MDX Life Sciences that provides real-time measurements of tissue metabolic activity in experimental models. The work provides a research framework for examining how changes in oxygen availability and carbon monoxide exposure can affect brain metabolism.
Carbon monoxide can interfere with the body's ability to use and transport oxygen, making it an important subject of research in understanding tissue hypoxia and impaired cellular metabolism.
The study explored the effects of carbon monoxide on mitochondrial activity and brain function. By using real-time metabolic measurements, researchers were able to observe changes in tissue metabolism during the experimental studies.
The MDX Viewer is designed to provide researchers with continuous metabolic measurements, allowing changes in tissue oxygen utilization and metabolic activity to be monitored over time.
According to Professor Mayevsky, the technology can help researchers evaluate differences in oxygen consumption between individual experimental subjects and quantify the effects of specific interventions on brain and organ metabolism.
“The MDX Viewer is an essential tool in quantifying the impact of oxygen on the brain and various organs,” said Professor Mayevsky. “The ability to monitor metabolic activity in real time provides researchers with a way to evaluate how different inputs affect tissue metabolism.”
The research is relevant to Bioxytran's broader interest in oxygen transport and tissue hypoxia.
When blood flow or oxygen availability is disrupted, tissues with high oxygen requirements, including the brain, can be particularly vulnerable to metabolic injury. Understanding how oxygen availability affects tissue metabolism is therefore an important area of research for conditions involving hypoxia and impaired circulation.
Bioxytran is developing BXT-25, an investigational oxygen transport technology being studied as part of the company's broader research into oxygen delivery and tissue hypoxia.
The company's research interests include conditions in which oxygen delivery may be compromised, including stroke and other neurological and degenerative conditions.
The MDX Viewer research provides a complementary scientific tool for studying the relationship between oxygen availability and tissue metabolism. It does not, however, establish the safety or efficacy of BXT-25 as a treatment for any medical condition.
One of the challenges in oxygen therapeutics research is determining how changes in oxygen availability translate into measurable changes within tissue.
Real-time metabolic monitoring may provide researchers with additional information when evaluating these relationships.
The MDX Viewer is intended to help researchers observe metabolic responses dynamically rather than relying solely on measurements taken at individual points in time.
This type of research may be useful in developing experimental models for conditions involving tissue hypoxia, impaired oxygen delivery, and metabolic stress.
For Bioxytran, these research capabilities complement its broader efforts to investigate technologies designed to address oxygen delivery and tissue injury.
Bioxytran's research portfolio extends across multiple areas of unmet medical need, including virology, oxygen therapeutics, and degenerative disease.
The company's scientific strategy includes investigating how changes in cellular and tissue-level biology can contribute to disease and how novel therapeutic approaches may address those mechanisms.
Within its oxygen therapeutics research, Bioxytran is investigating approaches designed to improve oxygen transport and delivery under conditions where normal oxygen supply may be compromised.
BXT-25 remains an investigational technology. Additional research and clinical evaluation are required to determine its potential safety, efficacy, and appropriate applications.
Bioxytran, Inc. is a clinical-stage biotechnology company developing novel therapeutic technologies based on carbohydrate drug design, glycovirology, galectin biology, and oxygen transport.
The company's research programs include ProLectin-M, an investigational galectin antagonist being developed for viral diseases, and BXT-25, an investigational oxygen transport technology being studied in connection with tissue hypoxia and neurological conditions.
Bioxytran's broader research interests include viral diseases, fibrosis, hypoxia, and degenerative disease.
For more information, visit www.bioxytraninc.com.
MDX Life Sciences develops technologies for monitoring and evaluating tissue metabolism. Its MDX Viewer is designed to provide researchers with real-time metabolic measurements that can be used in experimental studies involving oxygen utilization and tissue function.
This announcement contains forward-looking statements within the meaning of applicable federal securities laws. These statements may include statements concerning Bioxytran's research programs, BXT-25, oxygen transport technologies, potential applications of the MDX Viewer, future research activities, and the potential development of investigational technologies.
Forward-looking statements are subject to risks, uncertainties, assumptions, and other factors that could cause actual results to differ materially from those expressed or implied. These risks include, among others, research and development results, clinical trial outcomes, regulatory requirements, funding availability, intellectual property considerations, development timelines, and other factors described in Bioxytran's filings with the U.S. Securities and Exchange Commission.
Bioxytran undertakes no obligation to update or revise any forward-looking statements except as required by applicable law.
Bioxytran, Inc.
Website: www.bioxytraninc.com
Investor Contact:
Michael Sheikh
509-991-0245
mike.sheikh@bioxytraninc.com
